Eight Cutting-edge South Korean Bio Startups Begin Moving into Shonan iPark
Press Release
Sep 27, 2024
iPark Institute Co., Ltd.
Eight Cutting-edge South Korean Bio Startups Begin Moving into Shonan iPark
iPark Institute Co., Ltd. (Headquarters: Fujisawa City, Kanagawa Prefecture; CEO: Toshio Fujimoto; hereafter known as “iPark Institute”) and the Ministry of SMEs and Startups (Headquarters: Sejong Special Self-Governing City), a South Korean government agency, signed a business agreement in November of last year and held a Bioventure Ecosystem Roundtable in May this year. Following this, iPark Institute began providing concrete support to eight South Korean cutting-edge bio startups on September 26th.
The details of the partnership in support of startups in the South Korean advanced biotechnology field (cell therapy, gene therapy, and regenerative medicine), as set forth in the business agreement signed last November, are as follows:
● South Korean cutting-edge bio startups jointly selected by the two institutions will move into Shonan iPark, and the Ministry of SMEs and Startups will provide financial support for commercialization in Japan.
● The iPark Institute provides support for the use of laboratories and equipment at Shonan iPark.
The eight selected companies will move into the Shonan Health Innovation Park (hereafter known as “Shonan iPark”), where they will work with Japanese pharmaceutical companies and bio ventures to commercialize their products.
Company
Toshio Fujimoto, CEO of iPark Institute, commented on the move of the South Korean biotech startups:
“We are delighted to welcome eight bio startups from South Korea to Shonan iPark. Since its opening, Shonan iPark’s mission has been to build a life science ecosystem that is open to the world. We hope that with the addition of the South Korean startups, Japan and South Korea will collaborate to bring groundbreaking innovations in the life science field from Asia to the rest of the world.”
About iPark Institute Co., Ltd.
iPark Institute Co., Ltd. was established in 2023 with Industrial & Infrastructure Fund Investment Corporation (IIF), Takeda Pharmaceutical Company Limited (Takeda), and Mitsubishi Corporation as major shareholders. It took over the management of Shonan Health Innovation Park (Fujisawa City, Kanagawa Prefecture) in 2023, which Takeda has been responsible for since 2018. For more information about our company, please click here.
About Shonan Health Innovation Park (Shonan iPark)
Shonan iPark is Japan’s first pharmaceutical-initiated science park, created by Takeda Pharmaceutical Company Limited in April 2018 by opening its own research laboratories to the outside world. Currently operated by iPark Institute Co., Ltd. independent of Takeda Pharmaceutical Company Limited, the park aims to become a place where industry, government, and academia from a wide range of industries and sizes can come together to accelerate health innovation. Currently, the ecosystem is comprised of not only pharmaceutical companies, but also companies and organizations in nextgeneration medicine, cellular agriculture, AI, and government, with approximately 190 companies and more than 2,500 people (as of September 2024).
Click here for homepage
For the latest information on tenants and member companies at Shonan iPark, click here.
Official social links: YouTube / Facebook / X (former Twitter) / LinkedIn
For inquiries regarding this matter, please contact:
iPark Institute Co., Ltd., Communications
Attn: Takizawa, Tsukahara
Mail: iPi.PR@shonan-ipark.com